Collegium Pharmaceutical, Inc.
COLL
$28.23
$0.080.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 199.88M | 193.52M | 205.45M | 209.36M | 188.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 199.88M | 193.52M | 205.45M | 209.36M | 188.00M |
| Cost of Revenue | 21.22M | 20.80M | 21.60M | 21.66M | 22.19M |
| Gross Profit | 178.66M | 172.72M | 183.85M | 187.70M | 165.81M |
| SG&A Expenses | 104.41M | 86.35M | 66.67M | 65.55M | 72.70M |
| Depreciation & Amortization | 62.95M | 55.47M | 55.47M | 55.47M | 55.47M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 188.58M | 162.62M | 143.74M | 142.68M | 150.36M |
| Operating Income | 11.30M | 30.90M | 61.71M | 66.68M | 37.64M |
| Income Before Tax | -13.53M | 18.74M | 29.04M | 43.44M | 17.03M |
| Income Tax Expenses | 1.52M | 4.24M | 12.07M | 11.93M | 5.04M |
| Earnings from Continuing Operations | -15.05M | 14.50M | 16.96M | 31.51M | 11.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.05M | 14.50M | 16.96M | 31.51M | 11.98M |
| EBIT | 11.30M | 30.90M | 61.71M | 66.68M | 37.64M |
| EBITDA | 76.06M | 86.83M | 118.11M | 123.18M | 94.24M |
| EPS Basic | -0.46 | 0.45 | 0.54 | 1.00 | 0.38 |
| Normalized Basic EPS | -0.11 | 0.37 | 0.91 | 0.95 | 0.38 |
| EPS Diluted | -0.46 | 0.04 | 0.46 | 0.84 | 0.34 |
| Normalized Diluted EPS | -0.11 | 0.29 | 0.72 | 0.76 | 0.31 |
| Average Basic Shares Outstanding | 32.46M | 32.09M | 31.65M | 31.57M | 31.81M |
| Average Diluted Shares Outstanding | 32.46M | 40.07M | 40.08M | 39.44M | 39.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |